Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Thought Leadership
Latest Report
The US Payer Problem
The pharma world is on tenterhooks, waiting to see how the Inflation Reduction Act will impact drug innovation and pricing, and how the Federal Trade Commission could foil M&A plans. As valid as these concerns are, however, they shouldn't overshadow what is arguably a more pressing issue: the shifting dynamics in the US payer landscape. The…
Report library
Generative AI in Digital Health
As part of Evaluate’s partnership with Galen Growth, we are delighted to bring you this report on the emergence of artificial intelligence (AI) and the use of Generative…
Q3 Round Up: The Going Stays Tough
After a promising start to the year on the M&A front, things have slowed down significantly in the third quarter. While it was generally agreed that mega-mergers were…
Q3 Round Up 2023 Infographic
After a hopeful start in M&A for the year, did Q3 keep up the pace or change gears? Venture financing has seen a shift, and the IPO window appears to be nudging open.…
Clinical Strength in Digital Health
As part of Evaluate’s partnership with Galen Growth, we are delighted to bring you this report on the importance of clinical evidence within the digital healthcare…
World Preview 2023: Pharma's Age of Uncertainty
The pharmaceutical sector is entering new and unfamiliar territory. Key assumptions, such as the unrivalled profitability of the US market and the reliance on large…
H1 2023 Round Up Infographic
As we barrel into the second half of the year, it’s time to look back and make sense of what just happened. Download our infographic for a quick, data-packed overview of…
World Preview 2023 Infographic
Step into Pharma’s Age of Uncertainty, where all is in flux. From the FDA's shifting mood and the ripple effects of the IRA to commercial upheavals, dealmaking…
H1 Round Up: The haves and the have-nots
Starting 2023 in a rut, biopharma share prices sparked back to life in Q2, with a $141bn boost to the valuation of companies in the Evaluate Vantage universe. Yet, this…
ADA/EASL eBook
June saw the coming together of leading physicians, scientists, and healthcare professionals at two key metabolic conferences: ADA 2023 and EASL 2023. These meetings…
ASCO 2023 Round Up
The Evaluate Vantage team are back from the 2023 ASCO Annual Meeting in Chicago, where we've been reporting on all the big data drops and breakthroughs in cancer…